RWD RADAR generates patient cohort aggregate metrics, as well as offers metrics on the patient journey, from diagnosis to treatment modalities, and geographically, all based on real-world data available on Clinerion’s Patient Network Explorer platform. Patient cohort aggregate metrics show insights on disease-treatment relationships and disease-disease relationships, and are visualized as Top N lists, ranking the related concepts within a field code with the highest patient hits.
The statistics are based on real-time data and available with timestamps, allowing the generation of an incidence timeline. Data may be visualized aggregated, or geographically mapped, as well as showing gender and age distributions.
RWD RADAR can be used for epidemiology studies to look at disease occurrence, treatment metrics, differences by hospital, region, and country, as well as to identify differential treatment groups or cohorts by location, procedure or medication (segmentation by different treatment options and/or by drug/drug class).
Further developments under development by Clinerion include the installation of an infrastructure for deployment of artificial intelligence / machine learning algorithms.
For more information, click here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.